Last Updated: March 30, 2026

85+ Pharmaceutical Manufacturing Statistics for 2025-2026

The US pharmaceutical manufacturing sector is the most research-intensive industry in the country, spending more on R&D per dollar of revenue than any other sector. The US market reached $520.38 billion in 2025, accounts for roughly 45% of global pharmaceutical sales, and directly employs 1.3 million workers. In 2025 alone, drugmakers announced more than $370 billion in new US manufacturing commitments, the largest reshoring wave in the industry's history.

This global pharmaceutical manufacturing market report compiles over 85 data points from PhRMA, the Bureau of Labor Statistics, FDA, Census Bureau, Precedence Research, Grand View Research, PharmaSource, Mordor Intelligence, and other authoritative sources. Every statistic links to its original source for easy verification, citation, and research use. The page covers prescription drugs and over-the-counter products, market trends across the industry in the United States, global pharmaceutical manufacturing data, and pharmaceutical innovation benchmarks.

US Pharmaceutical Market Size and Growth

The US pharmaceutical market is the largest national drug market in the world by a wide margin. It leads global pharmaceutical spending, innovation, and drug approvals. The demand for pharmaceuticals continues to rise globally as populations age and chronic disease rates increase. These figures capture the scale of the industry in the United States and where it is expected to grow over the next decade, based on this global pharmaceutical manufacturing market report scope from leading research firms.

• The US pharmaceutical market was valued at $520.38 billion in 2025, up from $490.98 billion in 2024, per Precedence Research.
• The US market is projected to reach $907.86 billion by 2034, growing at a 6.34% compound annual growth rate (CAGR) from 2025 to 2034, per Precedence Research.
• The US accounts for approximately 45% of total global pharmaceutical sales, despite representing only 4% of global population, per Magnetaba citing industry data.
• The US represents roughly 22% of global pharmaceutical production by volume, per Magnetaba.
• North America holds 45% of global pharmaceutical sales, with the US as the dominant contributor, per Magnetaba.
• Oncology drugs represent the largest US therapeutic segment, comprising 16.79% of total pharmaceutical market revenue, driven by high incidence rates and innovative targeted therapies, per Magnetaba.
• Prescription drugs account for 87.23% of total US pharmaceutical market share, with over-the-counter (OTC) products comprising the remaining 12.77%, per Magnetaba.
• Global pharmaceutical spending is projected to surpass $1 trillion by 2030, with North America expected to retain its commanding share, per Magnetaba.
• Specialty drugs are projected to dominate future market spending, reflecting an ongoing shift toward high-cost, targeted therapies for chronic and rare conditions, per Magnetaba.
• Leading pharmaceutical companies driving these market trends include Pfizer, AbbVie, Johnson & Johnson, and Eli Lilly, which collectively shape global pharmaceutical innovation, pricing strategies, and supply chain infrastructure, per Magnetaba.

Employment and Workforce Statistics

Pharmaceutical manufacturing is one of the highest-paying sectors in US manufacturing. Direct employment exceeds 1.3 million workers, and the industry's economic multiplier effect supports nearly 5 million total US jobs. Here is what the employment data shows.

• Approximately 1.3 million people are directly employed in the US pharmaceutical industry, making it one of the largest manufacturing employers in the country, per Magnetaba.
• The pharmaceutical sector supports over 4.9 million total US jobs through direct employment and its multiplier effect on the broader economy, per Magnetaba.
• The biopharmaceutical industry generated over $800 billion in direct economic output in 2022, representing a critical contribution to national GDP and employment, per Magnetaba.
• NAICS 3254 (Pharmaceutical and Medicine Manufacturing) employment data is tracked by the Federal Reserve's Industrial Production series, with longitudinal employment data available from 1987 through 2024 via FRED St. Louis Fed.
• 60% of pharmaceutical usage is concentrated among adults aged 40 to 79, reflecting the sector's critical role in managing chronic disease in the aging US population, per Magnetaba.
• In 2025 alone, pharmaceutical companies announced more than $370 billion in US investment commitments over five years, creating tens of thousands of new manufacturing and research jobs, per Fierce Pharma.

Wages and Compensation Data

Pharmaceutical manufacturing pays some of the highest wages in all of US manufacturing. Biopharmaceutical workers earn more than double the average manufacturing wage nationally. The wage data below comes from BLS, PhRMA, and industry compensation surveys.

• Biopharmaceutical wages average over $157,000 per worker, which is more than three times the typical US manufacturing job wage and significantly higher than the national private-sector average, per Magnetaba.
• Chief executives in the pharmaceutical manufacturing sector can earn upwards of $315,300 annually, per BLS OEWS Pharmaceutical and Medicine Manufacturing (NAICS 325400).
• The pharmaceutical sector's wage premium above all US workers is among the highest of any manufacturing subsector, with biopharmaceutical industry workers earning more than 3x the national median wage, making it one of the most competitive labor markets in domestic manufacturing.

R&D Investment and Drug Development Costs

No industry spends more on research and development relative to its revenue than pharmaceuticals. The US pharmaceutical sector conducts over half of the world's pharmaceutical R&D. Understanding these figures is essential for grasping why drug pricing is so complex and why innovation cycles in this industry are measured in decades, not years.

• US pharmaceutical companies invested approximately $102 billion in R&D in 2021, representing a robust ongoing commitment to pharmaceutical innovation and drug advancement, per Magnetaba.
• PhRMA member companies' R&D spending reached approximately $96 billion worldwide in 2023, per PhRMA data via Statista.
• Pharmaceuticals accounted for 36.4% of all US manufacturing R&D, spending $150.3 billion in 2024, per BEA data via Manufacturing Lead Generation.
• The US pharmaceutical sector conducts over half of the world's total pharmaceutical R&D, per Magnetaba.
• Developing a single new drug costs an average of $2.6 billion and can take up to 15 years, per PhRMA data via Statista.
• Some estimates place the total ecosystem cost per successful drug approval above $5 billion, when accounting for all failed candidates across a development portfolio, per RD World / Deloitte analysis.
• Fewer than 10% of drugs entering Phase 1 clinical trials ultimately reach the market, underscoring the steep development attrition rate, per Magnetaba.
• R&D spending increased 25.8% while total pharmaceutical sales fell 15.6% during the period analyzed in one BERD study, illustrating the industry's intensifying commitment to innovation even under revenue pressure, per PMC / National Library of Medicine.
• R&D intensity accelerated from 11.9% to 17.7% of revenue over the study period, with a full-period mean of 13.4%, per PMC / National Library of Medicine.
• Between 1992 and 2004, the US accounted for 43.7% of all new molecular entities (NMEs) developed worldwide, per Magnetaba.
• Oncology drugs represent 38% of new product launches in recent years, with eight new pharmaceutical drugs launched in 2023 alone, per Magnetaba.
• Pfizer's drug development pipeline and AbbVie's intellectual property portfolio exemplify the scale of investment major pharmaceutical companies make to protect innovation and fund the next generation of treatments, per Magnetaba.
• Alzheimer's disease is one of the most heavily funded therapeutic areas for pharmaceutical R&D investment, reflecting the aging US population and the lack of effective disease-modifying treatments available today.
• Global pharmaceutical R&D investment has hit $276 billion annually when including all sources beyond PhRMA members, per RD World.

US Reshoring and Domestic Manufacturing Investment

2025 marked an inflection point for pharmaceutical manufacturing in the United States. Driven by supply chain vulnerabilities exposed during COVID-19, tariff concerns, and government incentives, major pharmaceutical companies announced an unprecedented wave of domestic manufacturing investment.

• Collectively, pharmaceutical companies announced more than $370 billion in US manufacturing investments over five years during 2025, the largest reshoring commitment in the industry's history, per Fierce Pharma.
• Total disclosed investment in pharmaceutical contract manufacturing (CDMO) capacity reached $24.86 billion in 2025, with a single month (September) accounting for $7.17 billion, per PharmaSource.
• 74% of all CDMO capital investment in 2025 flowed to the United States, with the US capturing $18.48 billion compared to second-place India's $3.31 billion and Switzerland's $610 million, per PharmaSource.
• Eli Lilly announced four new pharmaceutical manufacturing sites in the US in February 2025, part of a broader US capital expansion commitment, per DCAT Value Chain Insights.
• FUJIFILM Biotechnologies opened its $3.2 billion Holly Springs, North Carolina biologics manufacturing facility in September 2025, creating one of the world's largest single-site biologics manufacturing campuses, per PharmaSource.
• PharmaSource tracked 732 CDMO industry announcements in 2025, with 154 facility expansion announcements and 301 partnership announcements (41% of all tracked activity), per PharmaSource.
• The Trump administration's tariff announcements in April 2025 accelerated reshoring decisions, with pharmaceutical companies historically exempt from such duties now facing incentives to build domestic capacity proactively, per Think Global Health.

Supply Chain and API Sourcing Statistics

The US pharmaceutical supply chain has significant geographic concentration in India and China for active pharmaceutical ingredients (APIs). This dependency has become a strategic concern for policymakers and is one of the primary drivers of the reshoring wave described above.

• India accounts for approximately 21% of FDA-registered API manufacturing sites, China for 20%, and the US for 22%, per LGM Pharma.
• Over half of active pharmaceutical ingredients (APIs) for US prescription medicines come from India and the European Union, per US Pharmacopeia (USP).
• China contributes approximately 8% of total API volume used in US prescription medicines, though its share of certain antibiotic precursors is substantially higher, per USP.
• More than 500 US pharmaceutical facilities use continuous manufacturing and digital batch tracking to maintain FDA compliance and support domestic drug production, per Market Reports World.
• 64% of FDA-registered pharmaceutical manufacturing sites manufacture at least one application product under a BLA, NDA, or generic drug approval, per the FDA's FY 2024 Office of Pharmaceutical Quality Report.
• India's pharmaceutical manufacturing industry itself relies on China for approximately 70-80% of its own API inputs, creating a multi-tier supply chain concentration risk, per DrugPatentWatch.
• Supply chain security concerns and geopolitical pressures are the primary drivers behind the unprecedented reshoring wave, along with government policy incentives, per PharmaSource.

Pharmaceutical Exports by State

US pharmaceutical exports are geographically concentrated, with a handful of states and territories responsible for the overwhelming majority of export value. Puerto Rico has long been the single largest pharmaceutical export hub in the US system.

Source: Magnetaba, citing 2022 pharmaceutical export data.

• Puerto Rico leads all US states and territories in pharmaceutical exports, with $17.9 billion in trade value, reflecting decades of pharmaceutical manufacturing investment in the territory, per Magnetaba.
• Indiana ranks second nationally with $16.4 billion in pharmaceutical exports, driven by major manufacturing operations from companies including Eli Lilly, per Magnetaba.
• North Carolina ranks third with $11.1 billion in pharmaceutical exports, with its position set to grow significantly following FUJIFILM's $3.2 billion facility opening in Holly Springs, per Magnetaba.
• Generic drugs comprise approximately 84% of total US pharmaceutical sales volume, and the growing global demand for cost-effective generics is expanding US pharmaceutical export opportunities, per Magnetaba.

Biologics and Biosimilars Manufacturing

Biologics, including monoclonal antibodies, vaccines, and cell and gene therapies, are the fastest-growing segment of pharmaceutical manufacturing. The complexity of biologics production requires specialized facilities, skilled bioprocess engineers, and significantly higher capital investment than traditional small-molecule drug manufacturing.

• The global biologics market is projected to exceed $1.144 trillion by 2034, growing at an 11.05% CAGR driven by demand for monoclonal antibodies, vaccines, and personalized therapies, per BioSpace.
• Biologics and biosimilars are projected to outpace the broader pharmaceutical manufacturing market, expanding at a 10.85% CAGR through 2031 as blockbuster antibody patents expire and biosimilar competition expands, per Mordor Intelligence.
• Conventional drugs still led with 55.55% of pharmaceutical manufacturing revenue in 2025, but biologics are forecast to close the gap rapidly through the decade, per Mordor Intelligence.
• The global biopharmaceutical contract manufacturing market reached $44.61 billion in 2025, up from $40.14 billion in 2024, and is projected to reach $115.65 billion by 2034 at an 11.14% CAGR, per Towards Healthcare.
• Asia Pacific held 22.6% of the biopharmaceuticals market share in 2025, with the region forecasted to grow at 11.05% CAGR through 2034, fueled by China, India, and South Korea expanding local biologics manufacturing, per Credence Research.
• Biopharmaceutical contract manufacturing (CMO/CDMO) is projected to grow at 15.3% CAGR through 2032, with the manufacturing segment leading by service type in 2024, per Fortune Business Insights.
• Cell and gene therapy manufacturing is reaching industrial scale, with multiple CDMOs expanding advanced therapy manufacturing capabilities as clinical pipelines mature into commercial production, per PharmaSource.

Contract Manufacturing (CDMO) Statistics

Contract development and manufacturing organizations (CDMOs) play an increasingly central role in pharmaceutical production. As drug developers choose to outsource manufacturing and focus on R&D and commercial strategy, CDMOs handle the complex, capital-intensive work of actually making the drugs. This industry report on CDMO market trends shows explosive growth reflecting a structural shift in how pharmaceutical manufacturing is organized.

• Total CDMO investment tracked by PharmaSource reached $24.86 billion in 2025 across 732 industry announcements, with 154 facility expansions and 301 partnerships documented, per PharmaSource.
• The US captured $18.48 billion in CDMO investment in 2025, representing 74% of all disclosed global CDMO capital flows, per PharmaSource.
• FUJIFILM Biotechnologies' Holly Springs, NC facility is projected to grow its CDMO revenue from $1.3 billion to $5 billion within five years, with two-thirds of FUJIFILM's entire annual capital expenditure committed to this business segment, per PharmaSource.
• Samsung Biologics secured a $1.3 billion CDMO contract with a US biopharma partner in 2025, demonstrating that large Korean manufacturers are successfully competing for domestic US manufacturing business, per PharmaSource.
• Antibody-drug conjugate (ADC) manufacturing has become a dominant growth area for CDMOs, with multiple organizations racing to build bioconjugation capabilities to serve the expanding ADC pipeline, per PharmaSource.

Generic Drug Manufacturing Statistics

Generic drugs are the backbone of US pharmaceutical access. While they generate only a fraction of industry revenue, they fill the vast majority of prescriptions. The economics of generic drug manufacturing are sharply different from branded pharmaceuticals, with high volume, narrow margins, and intense global competition.

• Generic drugs account for approximately 84% of total pharmaceutical sales volume in the US, per Magnetaba.
• Generic drugs fill approximately 91% of all US prescriptions, making them the dominant dispensed form by volume at the point of care, per Magnetaba.
• Despite filling 91% of prescriptions, generics account for only approximately 8.5% of total pharmaceutical revenue, illustrating the dramatic price differential between branded and generic drugs, per Magnetaba.
• 87.2% of small molecule prescriptions are filled with unbranded generics, per Magnetaba.
• Brand-name drug prices in the US are more than 3.22 times higher than in countries with regulated pricing systems, per Magnetaba citing 2022 data.
• The Inflation Reduction Act empowers Medicare to negotiate drug prices, reshaping market dynamics for brand-name manufacturers and potentially accelerating generic adoption in targeted therapeutic categories, per Magnetaba.
• Nearly 50% of the US population uses prescription medications regularly, with 24.7% reporting three or more prescriptions in the last month and 13.5% using five or more, per Magnetaba.

Technology and Continuous Manufacturing

Pharmaceutical manufacturing is undergoing a technological transformation driven by advanced manufacturing technologies including continuous manufacturing, digital batch tracking, process analytical technology (PAT), and artificial intelligence. These advances are improving yields, reducing cycle times, and enhancing quality assurance across the sector. The adoption of these technologies represents a fundamental shift in how pharmaceutical drugs are produced at industrial scale.

• The pharmaceutical continuous manufacturing market is projected to grow at a 12.1% CAGR from 2024 to 2030, driven by FDA regulatory support and efficiency advantages over traditional batch manufacturing, per USD Analytics.
• The continuous manufacturing systems market overall is growing at a 12.04% CAGR through 2034, with pharmaceuticals and chemicals leading adoption, per Towards Healthcare.
• North America holds the largest share of the pharmaceutical continuous manufacturing market, supported by advanced drug delivery technologies and regulatory bodies that actively support continuous manufacturing practices, per IMARC Group.
• Finished product manufacturing drives 53.9% of continuous pharmaceutical manufacturing market demand, supported by increasing tablet production automation and integrated dosage form development, per Fact.MR.
• More than 500 US pharmaceutical facilities now use continuous manufacturing and digital batch tracking to maintain strict FDA compliance and support commercial drug supply, per Market Reports World.
• AI and digital investments are expected to reduce drug development timelines and improve clinical trial efficiency, with 30% of patients historically opting out of trials due to poor participant experience, per Magnetaba.
• Fill-finish capacity has expanded significantly across US and European CDMOs in response to surging demand for injectable medicines, including biologics and cell therapies, per PharmaSource.

Drug Development Pipeline Statistics

The pharmaceutical pipeline is the engine of future manufacturing growth. The data below quantifies the scope of drug development activity in the US, the attrition rates that make drug development so capital-intensive, and the therapeutic categories driving the most activity.

• In 2023, more than 5,500 pharmaceutical products were in various development phases globally, reflecting an all-time high in pipeline breadth driven by post-COVID innovation momentum, per Oakwood Labs.
• Fewer than 10% of drugs entering Phase 1 clinical trials successfully reach the market, making drug development one of the highest-attrition R&D processes in any industry, per Magnetaba.
• Developing a new drug averages $2.6 billion and up to 15 years from discovery to approval, per PhRMA data via Statista.
• Oncology drugs represent the largest and fastest-growing drug development category, comprising 38% of new product launches in recent years, per Magnetaba.
• Personalized medicine and targeted therapies are the dominant direction of future drug development, with biologics and specialty drugs projected to capture a growing share of both pipeline and revenue, per Magnetaba.
• Mergers and acquisitions (M&A) activity has risen significantly as companies seek to fill pipeline gaps through acquisition rather than internal discovery, a trend expected to continue through 2026, per Magnetaba.
• Patient enrollment challenges affect approximately 30% of clinical trial participants, who may opt out due to subpar participant experience, creating efficiency pressure that AI-driven trial management tools are beginning to address, per Magnetaba.
• Out-of-pocket drug spending in the US was projected to peak at $52.5 billion in 2023, highlighting the consumer financial burden that policy initiatives like the Inflation Reduction Act aim to reduce, per Magnetaba.

What These Statistics Mean for Manufacturers and Suppliers

Pharmaceutical manufacturing is one of the most demanding, highest-value, and fastest-growing sectors of US industrial production. The data here tells a coherent story: the US is the world's dominant pharmaceutical market, the industry is reshoring manufacturing at historic scale, and the shift toward biologics and personalized medicine is creating entirely new categories of manufacturing complexity and capital need.

For manufacturers and B2B suppliers, several patterns stand out. First, the $370 billion in announced domestic manufacturing investment over five years creates an enormous pipeline of facility construction, equipment procurement, and specialized services contracts. Companies with capabilities in cleanroom design, bioprocessing equipment, HVAC validation, water-for-injection (WFI) systems, and pharmaceutical-grade materials are facing a generational demand opportunity.

Second, the shift to biologics manufacturing (growing at 10.85-15.3% CAGR) requires fundamentally different manufacturing infrastructure than small-molecule drug production. Bioreactors, cell culture systems, chromatography equipment, and aseptic fill-finish lines are in acute demand globally. Manufacturers and engineering firms with life sciences credentials are well-positioned to compete for this work.

Third, the API supply chain concentration in India and China is a strategic vulnerability that US policy and corporate strategy are both working to correct. Companies that can manufacture pharmaceutical-grade APIs or precursor chemicals domestically are entering a favorable competitive environment with strong demand tailwinds.

Cite This Report

Sources